ГоловнаArchive of numbers2022Volume 30, issue 1 (110)Protocol for the treatment of patients with a spectrum of opiomyelitis-associated diseases using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Title of the article Protocol for the treatment of patients with a spectrum of opiomyelitis-associated diseases using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Authors Voloshyna Natalia
Vasylovskyi Vitalii
Chernenko Maksym
In the section HELP TO PRACTICAL PHYSICIAN
Year 2022 Issue Volume 30, issue 1 (110) Pages 80-84
Type of article Scientific article Index UDK Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V30-is1-2022-15
Key words
Access to full text version of the article pdf download
Bibliography 1. Modi G. Demyelinating disorder of the central nervous system occurring in black South Africans. Journal of Neurology, Neurosurgery & Psychiatry. 2001. Vol. 7. No. 4. Р. 500—505.
2. D. M. Wingerchuk, В. Banwell, J. Вennett et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. 85(2). Р. 177—189. DOI: 10.1212/ WNL.0000000000001729.
3. Yavorskaya V. A., Grebenyuk A. V., Severin Yu. V., Krivchun V. M. Zabolevaniya spektra optikonevromielita: Obzor sovremennyih dannyih i sobstvennyie klinicheskie nablyudeniya. Georgian Medical News. 2019. No. 6 (291). S. 74—81. URL: https://cdn.website-editor.net/480918712df344a4a77508d4c d7815ab/files/uploaded/V291_N6_June_2019.pdf.
4. Wingerchuk D. M. The spectrum of neuromyelitis optica. The Lancet Neurology. 2007. Vol. 6, no. 9. Р. 805—815.
5. Jarius S., Wildemann B. The history of neuromyelitis optica. Journal of neuroinflammation 2013. Vol. 10, no. 1. Р. 797.
6. Lennon V. A. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. The Lancet. 2004. Vol. 364, no. 9451. Р. 2106—2112.
7. Lennon V. A. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. Journal of Experimental Medicine. 2005. Vol. 202, no. 4. Р. 473—477.
8. Wingerchuk D. M., Weinshenker B. G. Neuromyelitis optica (Devic’s syndrome). Handbook of clinical neurology. Elsevier. 2014. Vol. 122. P. 581—599.
9. Drori T., Chapman J. Diagnosis and classification of neuromyelitis optica (Devic’s syndrome). Autoimmunity reviews. 2014. Vol. 13, 4—5. Р. 531—533.
10. Asgari N. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011. Vol. 76, no. 18. Р. 1589—1595.
11. Saadoun S. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces  neuromyelitis optica lesions in mice. Brain. 2010. Vol. 133, Issue 2. Р. 349—361. DOI: https://doi.org/10.1093/brain/awp309.
12. S. Jarius, F. Aboul-Enein, P. Waters et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008. Vol. 131 (11). Р. 3072—3080. DOI: 10.1093/brain/awn240.
13. T. Takahashi, K. Fujihara, I. Nakashima et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007. Vol. 130 (5). Р. 1235—1243. DOI: 10.1093/brain/awm062.
14. M. F. Pittenger, A. M. Mackay, S. C. Beck et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. 284(5411). Р. 143—147. DOI: 10.1126/science.284.5411.143. 15. N. R. Blondheim, Y. S. Levy, T. A. Ben-Zur et al. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Development. 2006. Vol. 15, No. 2 Р. 141—164. DOI: 10.1089/scd.2006.15.141.
16. Kassis I., Vaknin-Dembinsky A., Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther. 2011. 6 (1). Р. 63—68. DOI: 10.2174/157488811794480762.
17. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007. 28 (5). Р. 219—226. DOI: 10.1016/j.it.2007.03.001.
18. Ben-Hur T. Immunomodulation by neural stem cells. J Neurol Sci. 2008. 265 (1—2). Р. 102—104. DOI: 10.1016/j. jns.2007.05.007.
19. Nauta A. J., Fibbe W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007. 110 (10). Р. 3499— 3506. DOI: 10.1182/blood-2007-02-069716.
20. I. Kassis, N. Grigoriadis, B. Gowda-Kurkalli et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. 2008. 65 (6). Р. 753—761. DOI: 10.1001/archneur.65.6.753.
21. E. Zappia, S. Casazza, E. Pedemonte et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005. Vol. 106, Issue 5. Р. 1755—1761. DOI: 10.1182/blood-2005-04-1496.
22. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008. No. 8. Р. 726—736. DOI: 10.1038/nri2395.
23. V. K. Harris, Q. J. Yan, T. Vyshkina et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2012. 313 (1-2). 167—177. DOI: 10.1016/j.jns.2011.08.036.
24. Pluchino S., Quattrini A., Brambilla E. et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003. 422: 688—94. DOI: 10.1038/nature01552.
25. Pluchino S., Gritti A., Blezer E. et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009. 66: 343—54. DOI: 10.1002/ana.21745. 26. T. Ben-Hur, O. Einstein, R. Mizrachi-Kol et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003. No. 41. Р. 73—80. DOI: 10.1002/glia.10159.
27. Karussis D., Petrou P., Kassis I. Clinical experience with stem cells and other cell therapies in neurological diseases. J Neurol Sci. 2013. 324 (1-2). Р. 1—9. DOI: 10.1016/j.jns.2012.09.031.
28. J. Chen, Y. Li, L. Wang et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001. 189 (1—2). Р. 49—57. DOI: 10.1016/s0022-510x(01)00557-3.
29. D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010. No. 67 (10). Р. 1187—1194. DOI: 10.1001/archneurol.2010.248.
30. P. H. Lee, J. E. Lee, H. S. Kim et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012. Vol. 72, Issue 1. Р. 32—40. DOI: 10.1002/ana.23612.
31. P. Petrou, Y. Gothelf, Z. Argov et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016. 73 (3). Р. 337—344. DOI: 10.1001/jamaneurol.2015.4321. 32. D. Karussis, I. Kassis, B. G. Kurkalli, S. Slavin, Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. 2008. Vol. 265, Issues 1–2. Р. 131—135. DOI: 10.1016/j.jns.2007.05.005.
33. Berry J. D., Cudkowicz M. E., Windebank A. J et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, biomarker results. Neurology. 2019. 93 (24): e2294-e2305. DOI: 10.1212/WNL.0000000000008620.
34. J. D. Glass, V. S. Hertzberg, N. M. Boulis et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016. 87 (4). Р. 392—400. DOI: 10.1212/WNL.0000000000002889.
35. V. K. Harris, J. Stark, T. Vyshkina et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 2018. No. 29. Р. 23—30. DOI: 10.1016/j.ebiom.2018.02.002.
36. P. M. Connick, C. Crawley, D. J. Webber et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012. Vol. 11, Issue 2. Р. 150—156. DOI: 10.1016/S1474-4422(11)70305-2.
37. O. Fernandez, G. Izquierdo, V. Fernandez et al. Adiposederived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE. 2018. 13 (5): e0195891. DOI: 10.1371/journal. pone.0195891.
38. S. Llufriu, M. Sepulveda, Y. Blanco et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE. 2014. 9 (12): e113936. DOI: 10.1371/journal.pone.0113936.
39. F. D. Lublin, J. D. Bowen, J. Huddlestone et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014. Vol. 3, Issue 6. Р. 696—704. DOI: 10.1016/j.msard.2014.08.002.
40. P. Petrou, I. Kassis, N. Levin et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020. 143 (12). Р. 3574—3588. DOI: 10.1093/brain/awaa333.
41. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Schegelskaya E. A. Autoterapiya kletkami stromyi kostnogo mozga (KSKM), indutsirovannyimi v nervnyie, bolnyih s hronicheskimi zabolevaniyami TsNS (rasseyannyiy skleroz, bolezn Parkinsona). Ukrainskyi neirokhirurhichnyi zhurnal. 2003. No. 3. URL: https:// cyberleninka.ru/article/n/autoterapiya-kletkami-stromy-kostnogo-mozga-indutsirovannymi-v-nervnye-bolnyh-s-hronicheskimizabolevaniyami-tsns-rasseyannyy-skleroz. 42. E. Eggenhofer, V. Benseler, A. Kroemer et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012. Vol. 3: 297. DOI: 10.3389/fimmu.2012.00297.
43. Voloshyna N. P., Vasylovskyi V. V., Mikulynskyi Yu. Yu., Shchehelska O. A. Patent UA 68711 A. «Sposib likuvannia khvorykh na rozsiianyi skleroz» vid 02.10.2003. Kyiv. Ukrpatent.
44. Voloshina N. P., Vasilovskiy V. V. Eticheskie voprosyi v lechenii bolnyih rasseyannyim sklerozom (autoterapiya stromalnyimi kletkami kostnogo mozga, indutsirovannyimi v nervnyie). Kultura narodov Prichernomorya. 2004. No. 56. T. 2. R. 185—186